Literature DB >> 29460105

The importance of standardisation of measurement and reference intervals for detection of phaeochromocytoma and paraganglioma (PPGL).

Tomás P Griffin1, Delia Bogdanet1, Patrick Navin2, Grace Callagy3, Paula M O'Shea4, Marcia Bell5.   

Abstract

A 51-year-old male presented 25 years ago with excessive sweating and haematuria. Blood pressure was labile. CT abdomen showed a large right-sided adrenal mass. Two 24-h urine collections showed elevated urinary catecholamines. Right adrenal resection was performed; a phaeochromocytoma (PC) was confirmed histologically. Two decades later, the patient represented with excessive sweating and measured variable blood pressure readings. Measurement of plasma metanephrines (PMets) showed elevated normetanephrine (NMN) [50,250 (R.I. 0-1180) pmol/L] and metanephrine (MN) [1030 (R.I. 0-510) pmol/L] values. CT abdomen showed a 100 × 90 × 63 mm enhancing mass in the right retroperitoneum. Curative resection was undertaken confirming recurrent PC. Follow-up post-resection, plasma NMN was discordant, 1314 pmol/L (above decision threshold) at 30 min and 911 pmol/L (below decision threshold) at 40 min. Acute clinical awareness of persistent disease mandated the performance of a metaiodobenzylguanidine (MIBG) scan and CT abdomen. These confirmed residual disease in the upper right side of the retroperitoneum. Persistent disease following redo surgery could have been missed if only seated-sampling upper reference limits were applied to PMets collected at 40 min. Our experience with this patient triggered a review of our PMets sampling strategy. There was no statistically significant difference in PMets sampled at 30 and at 40 min seated-rest. Optimum diagnostic test accuracy was achieved using a supine-sampling strategy at a single time point (30 min). Our case highlights the importance of maintaining a high index of clinical suspicion for residual/recurrent disease in the face of inconclusive biochemistry, followed by appropriate targeted radiology using MIBG or PET-CT in patients with PPGL.

Entities:  

Keywords:  Phaeochromocytoma; Plasma Metanephrines

Mesh:

Year:  2018        PMID: 29460105     DOI: 10.1007/s11845-018-1756-7

Source DB:  PubMed          Journal:  Ir J Med Sci        ISSN: 0021-1265            Impact factor:   1.568


  28 in total

1.  Biochemical diagnosis of pheochromocytoma: which test is best?

Authors:  Jacques W M Lenders; Karel Pacak; McClellan M Walther; W Marston Linehan; Massimo Mannelli; Peter Friberg; Harry R Keiser; David S Goldstein; Graeme Eisenhofer
Journal:  JAMA       Date:  2002-03-20       Impact factor: 56.272

Review 2.  Hypertension: The role of biochemistry in the diagnosis and management.

Authors:  P M O'Shea; T P Griffin; M Fitzgibbon
Journal:  Clin Chim Acta       Date:  2016-12-19       Impact factor: 3.786

3.  Malignant pheochromocytoma. Chromaffin granule transmitters and response to treatment.

Authors:  F Rao; H R Keiser; D T O'Connor
Journal:  Hypertension       Date:  2000-12       Impact factor: 10.190

4.  Plasma and urinary metanephrines determined by an enzyme immunoassay, but not serum chromogranin A for the diagnosis of pheochromocytoma in patients with adrenal mass.

Authors:  N Unger; J Hinrichs; T Deutschbein; H Schmidt; M K Walz; K Mann; S Petersenn
Journal:  Exp Clin Endocrinol Diabetes       Date:  2012-06-13       Impact factor: 2.949

5.  A comparison of biochemical tests for pheochromocytoma: measurement of fractionated plasma metanephrines compared with the combination of 24-hour urinary metanephrines and catecholamines.

Authors:  Anna M Sawka; Roman Jaeschke; Ravinder J Singh; William F Young
Journal:  J Clin Endocrinol Metab       Date:  2003-02       Impact factor: 5.958

6.  Comparison of free plasma metanephrines enzyme immunoassay with (131)I-MIBG scan in diagnosis of pheochromocytoma.

Authors:  Yun-Chao Gao; Han-Kui Lu; Quan-Yong Luo; Li-Bo Chen; Ying Ding; Rui-Sen Zhu
Journal:  Clin Exp Med       Date:  2008-07-11       Impact factor: 3.984

7.  Free plasma metanephrines as a screening test for pheochromocytoma in low-risk patients.

Authors:  Jan Václavík; David Stejskal; Borek Lacnák; Marie Lazárová; Libor Jedelský; Lenka Kadalová; Marie Janosová; Zdenek Frysák; Petr Vlcek
Journal:  J Hypertens       Date:  2007-07       Impact factor: 4.844

8.  Plasma free metanephrines are superior to urine and plasma catecholamines and urine catecholamine metabolites for the investigation of phaeochromocytoma.

Authors:  Peter E Hickman; Michelle Leong; Julia Chang; Susan R Wilson; Brett McWhinney
Journal:  Pathology       Date:  2009-02       Impact factor: 5.306

Review 9.  European Society of Endocrinology Clinical Practice Guideline for long-term follow-up of patients operated on for a phaeochromocytoma or a paraganglioma.

Authors:  P F Plouin; L Amar; O M Dekkers; M Fassnacht; A P Gimenez-Roqueplo; J W M Lenders; C Lussey-Lepoutre; O Steichen
Journal:  Eur J Endocrinol       Date:  2016-05       Impact factor: 6.664

10.  Plasma methoxytyramine: clinical utility with metanephrines for diagnosis of pheochromocytoma and paraganglioma.

Authors:  Dipti Rao; Mirko Peitzsch; Aleksander Prejbisz; Katarzyna Hanus; Martin Fassnacht; Felix Beuschlein; Christina Brugger; Stephanie Fliedner; Katharina Langton; Christina Pamporaki; Volker Gudziol; Anthony Stell; Andrzej Januszewicz; Henri J L M Timmers; Jacques W M Lenders; Graeme Eisenhofer
Journal:  Eur J Endocrinol       Date:  2017-05-05       Impact factor: 6.664

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.